About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at $4.09, a -0.73 Surge/Plunge – DwinneX

Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at $4.09, a -0.73 Surge/Plunge

Nora Barnes

In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.

Adverum Biotechnologies Inc (NASDAQ: ADVM) closed the day trading at $4.09 down -0.73% from the previous closing price of $4.12. In other words, the price has decreased by -$0.73 from its previous closing price. On the day, 0.56 million shares were traded. ADVM stock price reached its highest trading level at $4.16 during the session, while it also had its lowest trading level at $3.9914.

On June 25, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $25. On April 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on April 30, 2024, with a $30 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 15 ’25 when Soparkar Peter sold 2,960 shares for $2.00 per share. The transaction valued at 5,920 led to the insider holds 39,154 shares of the business.

Seyedkazemi Setareh sold 924 shares of ADVM for $1,848 on May 15 ’25. The CHIEF DEVELOPMENT OFFICER now owns 13,768 shares after completing the transaction at $2.00 per share. On May 15 ’25, another insider, Fischer Laurent, who serves as the CEO, PRESIDENT AND DIRECTOR of the company, sold 9,126 shares for $2.00 each. As a result, the insider received 18,252 and left with 87,488 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADVM now has a Market Capitalization of 90296848 and an Enterprise Value of 153176848.

Stock Price History:

The Beta on a monthly basis for ADVM is 0.86, which has changed by -0.36124033 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, ADVM has reached a high of $6.98, while it has fallen to a 52-week low of $1.78. The 50-Day Moving Average of the stock is -5.92%, while the 200-Day Moving Average is calculated to be 17.84%.

Shares Statistics:

Over the past 3-months, ADVM traded about 628.32K shares per day on average, while over the past 10 days, ADVM traded about 401760 shares per day. A total of 22.00M shares are outstanding, with a floating share count of 13.76M. Insiders hold about 37.66% of the company’s shares, while institutions hold 40.10% stake in the company. Shares short for ADVM as of 1763078400 were 811403 with a Short Ratio of 1.56, compared to 1760486400 on 875370. Therefore, it implies a Short% of Shares Outstanding of 811403 and a Short% of Float of 4.16.

Earnings Estimates

The dynamic stock of Adverum Biotechnologies Inc (ADVM) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.35 and low estimates of -$1.98.

Analysts are recommending an EPS of between -$7.68 and -$8.73 for the fiscal current year, implying an average EPS of -$8.23. EPS for the following year is -$3.58, with 5.0 analysts recommending between -$1.28 and -$8.25.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.